Younger Patients Who Survive Non-Hodgkin Lymphoma Face Higher Risk of Comorbidities
Researchers sought to determine the risk of comorbidities in younger patients who survive NHL compared with older patients.
Non-Hodgkin Lymphoma
CK1-Alpha May Be a Promising Therapeutic Target for Patients With Mantle Cell Lymphoma
Researchers sought to determine whether CK1-alpha would be a viable target in patients with mantle cell lymphoma.
Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Therapy for Non-Hodgkin Lymphoma
Researchers sought to determine whether prophylactic tocilizumab prior to anti-CD19 CAR-T therapy would be feasible for patients with NHL.
CAR-T Cell Therapy Improves Outcomes vs Salvage Therapy in Refractory LBCL
Researchers sought to determine whether CAR-T therapy would have better long-term clinical outcomes in patients with LBCL compared with salvage therapy.
Zanubrutinib Shows Promising Response Rate in Relapsed, Refractory Marginal Zone Lymphoma
Researchers sought to determine whether zanubrutinib would have a positive response in patients with relapsed/refractory marginal zone lymphoma.
Effect of Bundle Nursing on Thrombosis Risk in Patients With Non-Hodgkin Lymphoma
A single-institution study determined the effect of a novel nursing practice on incidence of PICC-UEDVT, outcomes, and satisfaction with care in patients with NHL.
Patients With B-Cell Non-Hodgkin Lymphoma Treated With Anti-CD20 Antibodies Have Impaired Response to COVID-19 Vaccine
Researchers sought to determine whether patients with B-NHL who had treatment with anti-CD20 antibodies had an impaired serological response to an mRNA COVID-19 vaccine.
Combination Antiretroviral Therapy and CD4/CD8 Ratio on the Risk for Kaposi Sarcoma, Non-Hodgkin Lymphoma in Patients With HIV Infection
Researchers sough to assess the relationship between CD4/CD8 ratios and the risk for Kaposi sarcoma and non-Hodgkin lymphoma among patients with HIV infection treated with combination antiretroviral therapy.
Orelabrutinib and MIL62 Combination Therapy Well Tolerated for Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Researchers sought to determine whether orelabrutinib and MIL62 combination therapy would be safe and effective in patients with relapsed/refractory NHL.
Glofitamab Step-Up Dosing Efficacy Data Show High Complete Response Rates in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Researchers sought to determine whether glofitamab monotherapy would have high preliminary response rates in patients with R/R non-Hodgkin lymphoma.
- Loading...
Loading...
Loading... 
Loading...